Compounding Pharmacies' Lawsuit Against FDA Will Continue - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Compounding Pharmacies' Lawsuit Against FDA Will Continue

Pharmaceutical Technology

Compounding Pharmacies' Lawsuit Against FDA Will Continue

The US District Court for the Western District of Texas (Midland, TX) has ruled that a lawsuit against the US Food and Drug Administration will proceed, despite a request from FDA to drop the case.

A coalition of 10 compounding pharmacies hit FDA with a lawsuit for engaging in “unlawful” inspections of state-regulated pharmacies. At the center of the lawsuit is FDA’s 2003 compliance policy guideline (CPG 7125.40), which prohibits the compounding of drugs from bulk ingredients.  The agency has since inspected several compounding pharmacies to enforce the guidelines.

The pharmacies petitioned the court to allow them to continue using compounding methods without FDA considering them a manufacturer or requiring them to meet the agency’s manufacturing guidelines. The coalition alleges that federal law prohibits FDA from inspecting state-regulated pharmacies and that the agency is exercising jurisdiction without the authority to do so.

–Kaylynn Chiarello

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here